Novartis Fabhalta® (iptacopan) IgA Nephropathy Phase III Results
Fabhalta® (iptacopan) Demonstrates Positive Results in IgA nephropathy Trial
Table of Contents
Published October 16, 2024
Significant Slowing of Kidney Function decline Observed
Novartis has announced that its investigational oral complement inhibitor, Fabhalta® (iptacopan), has successfully met the primary endpoint in a Phase III clinical trial evaluating its efficacy in patients with IgA nephropathy (IgAN). the trial demonstrated a statistically significant slowing of kidney function decline, as measured by estimated glomerular filtration rate (eGFR), compared to placebo.IgAN is a chronic autoimmune disease and a leading cause of kidney failure globally.
Understanding the Trial Results
The Phase III trial assessed the impact of Fabhalta® on patients with IgAN who were already receiving standard-of-care treatment, typically an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). The results indicate that adding iptacopan to existing therapies provides an additional benefit in preserving kidney function. this is particularly significant as IgAN often progresses slowly, but inevitably, towards end-stage renal disease requiring dialysis or transplantation.
how Fabhalta® Works
Fabhalta® targets factor B, a key protein in the alternative pathway of the complement system. Overactivation of this pathway is implicated in the pathogenesis of IgAN, leading to inflammation and damage within the kidneys. By selectively inhibiting factor B, iptacopan aims to reduce this harmful inflammation and protect kidney function. This mechanism of action differentiates it from other complement-targeted therapies.
Next Steps and Potential Impact
Novartis intends to submit these Phase III trial results to regulatory authorities, including the U.S. Food and Drug Governance (FDA) and the European Medicines Agency (EMA), seeking approval for Fabhalta® as a treatment for IgAN. If approved, Fabhalta® coudl represent a significant advancement in the management of this debilitating disease, offering a new therapeutic option to slow disease progression and potentially delay or prevent the need for dialysis or kidney transplantation. The company anticipates potential regulatory action in 2025.